Comparing Imaging Techniques for Myeloma Response Assessment | Marco Talarico, MD, PhD(c) | #IMS2025

Comparing Imaging Techniques for Myeloma Response Assessment | Marco Talarico, MD, PhD(c) | #IMS2025
Choosing Between CAR-T and Bispecific Antibodies: Patient Perspectives | Valeria Escobedo | #IMS2025
Patient Reported Outcomes (PROs) indicate Linvoseltamab Improves QOL | Joshua Richter, MD | #IMS25
High-Risk Myeloma -CONCEPT Trial-Isatuximab, Kyprolis, Revlmid, Dex. |Lisa Leypoldt, MD #ims25
Likely Change in IMWG Myeloma Response Criteria : 24-Hour Urine & More | Rahul Banerjee, MD | #IMS25
Maintenance Therapy : Revlimid vs. Revlimid + Dara | AURIGA Update| Larry Anderson, MD, PhD | #ims25
Dara- Revlimid, Ixazomib & Dex: A Promising Option for Some Myeloma Patients| Andrew Yee, MD #IMS25
Updates from IMS on CAR-T & Bispecifics in Myeloma | Rahul Banerjee, MD | #IMS2025
Ide-cel Efficacy in Myeloma Correlates with Endogenous Immune Profiles | Bruno Paiva, PhD | #IMS25
What Drives Myeloma Treatment Decisions After Relapse? | Paola Anchondo | #IMS2025
Using Cevostamab Consolidation After CAR-T to Improve Outcomes | Adam Cohen, MD | #IMS25 #myeloma
MGIP: The Earliest Warning Sign of Myeloma Evolution | Sungjae Kim, PhD | #IMS2025
CELMoDs: Boosting T-Cell Therapies with Iberdomide & Mezigdomide | Joshua Richter, MD| #IMS2025